Biotech Values

[HeroicEmpire46]

Enanta (ENTA) views
Hello, I see this is an active board for Enanta. I have become an investor in Enanta recently mainly for their RSV portfolio but also for their potential in other ID's. Seems like an important area to be invested in given coivd, bird flu etc. However recently i have started having doubts over managements credibility. Since developing the PI's for HCV (for which they needed Abbvies NS5a) they have seemed very indecisive. A glance at their portfolios since their IPO indicate they have started the development of multiple drugs in various indications and then stopped after early studies either due to a far from ideal profile or their drug being outdated . This indicates that Enanta has issues with how they select a drug from a portfolio of candidates which indicates a problem with upper management. I was aware of this and invested anyway since I had thought that at some point they would pull things together but their recent indecisiveness with EDP-938 seems to indicate they have no clear plan. The entry into immunology seems promising but there are numerous competitors targeting the same MOA. Some urgency seems to be required which I don't see management showing. For example the KIT drug will enter ind enabling activities sometime in 25 but there is no guidance of when clinical trials will start. On the other hand third harmonic and blueprint have both submitted ind's pretty soon after selecting a candidate. Based on their history since the IPO their drug development speed seems very lethargic to say the least.

I think the company is in a decent position with some recurring revenue from their HCV drug portfolio but I'm not sure how long that revenue stream will last. It seems to be they need to be quick and decisive and I don't think Jay Luly is the answer. I'm curious what others think of him? I'm a retail investor with a 6 figure investment but I would prefer a change at the top to consider further investment. Any thoughts on Jay luly's performance or the possibility of replacing him would be appreciated. TIA